日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma

高通量药物筛选鉴定出治疗低级别浆液性卵巢癌的新型疗法

Kathleen I Pishas ,Karla J Cowley ,Marta Llaurado-Fernandez ,Hannah Kim ,Jennii Luu ,Robert Vary ,Nikola A Bowden ,Ian G Campbell ,Mark S Carey ,Kaylene J Simpson # ,Dane Cheasley #

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

高级别浆液性卵巢癌中 SLC25A40-ABCB1 融合的耐药性以外的表型后果

Kathleen I Pishas, Karla J Cowley, Ahwan Pandey, Therese Hoang, Jessica A Beach, Jennii Luu, Robert Vary, Lorey K Smith, Carolyn E Shembrey, Nineveh Rashoo, Madelynne O White, Kaylene J Simpson, Andrea Bild, Jason I Griffiths, Dane Cheasley, Ian Campbell, David D L Bowtell, Elizabeth L Christie

The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density

乳腺密度高或低的女性患乳腺癌时,TP53 突变率有所不同

Dane Cheasley, Lisa Devereux, Siobhan Hughes, Carolyn Nickson, Pietro Procopio, Grant Lee, Na Li, Vicki Pridmore, Kenneth Elder, G Bruce Mann, Tanjina Kader, Simone M Rowley, Stephen B Fox, David Byrne, Hugo Saunders, Kenji M Fujihara, Belle Lim, Kylie L Gorringe #, Ian G Campbell #